The Metabolic Effects of Intermittent Fasting
The Effects of Fasting on Reprogramming of Lipid Metabolism and Bone Metabolism
2 other identifiers
interventional
90
1 country
1
Brief Summary
Caloric restriction has beneficial metabolic effects in humans including weight loss and improvement in blood pressure and lipid levels. Intermittent fasting has emerged as a popular alternative to caloric restriction as it does not require daily adherence to a dietary protocol, but whether the benefits of fasting protocols are dependent on weight loss is not known. In this study, the investigators will explore the metabolic effects of fasting and evaluate whether these effects, including negative effects on bone metabolism, are independent of weight loss.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2023
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 27, 2023
CompletedFirst Posted
Study publicly available on registry
February 10, 2023
CompletedStudy Start
First participant enrolled
October 25, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2028
August 7, 2025
August 1, 2025
4.7 years
January 27, 2023
August 2, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Triglyceride carbon content and degree of saturation
Change in triglyceride carbon content and degree of saturation (% variation explained by both carbon number and double bond number in a regression model) between Baseline and Final Intervention visits
Baseline, 3 months
Trabecular bone microarchitecture
Change in trabecular bone volume fraction at the radius between Baseline and Final Intervention visits
Baseline, 3 months
Secondary Outcomes (1)
Insulin sensitivity
Baseline, 3 months
Study Arms (3)
Fasting
EXPERIMENTALSubjects will fast one-day per week for 12 weeks
Fasting with weight maintenance
EXPERIMENTALSubjects will fast one-day per week for 12 weeks and maintain body weight
Counseling
PLACEBO COMPARATORSubjects will be counseled on optimal diet and activity recommendations to maintain/achieve a normal BMI (standard of care)
Interventions
Study participants will fast one day per week for 12 weeks
Study participants will be counseled to maintain body weight
Study participants will be counseled on optimal diet and activity recommendations for maintaining/achieving a normal BMI
Eligibility Criteria
You may qualify if:
- Men and women, ages 21-45 years
- BMI of at least 21 kg/m2 and up to and including BMI of 29 kg/m2
- Normal thyroid function
- Regular menses (women)
- At least one first-degree relative with type 2 diabetes (T2D) and/or history of gestational diabetes
You may not qualify if:
- Any chronic diseases including hypertension and Type 2 diabetes mellitus
- Indication for lipid-lowering therapy in non-diabetics, using the more stringent AHA guideline cutoff (LDL\>190 or an estimated 10-year ASCVD risk of \>7.5%)
- Chronic medications, including oral contraceptive pills
- Pregnant and/or breastfeeding
- History of an eating disorder
- OH vitamin D level \< 20 ng/mL
- Active substance abuse, including alcohol
- Subjects with a prior history of intermittent fasting
- The study physician feels that the subject may not be able to safely complete the protocol or may place themselves at risk by undergoing the protocol
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
Related Publications (1)
Quaytman JA, David NL, Venugopal S, Amorim T, Beatrice B, Toledo FGS, Miller RG, Steinhauser ML, Fazeli PK. Intermittent fasting for systemic triglyceride metabolic reprogramming (IFAST): Design and methods of a prospective, randomized, controlled trial. Contemp Clin Trials. 2024 Nov;146:107698. doi: 10.1016/j.cct.2024.107698. Epub 2024 Sep 17.
PMID: 39299543DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Pouneh Fazeli, MD
University of Pittsburgh
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor of Medicine
Study Record Dates
First Submitted
January 27, 2023
First Posted
February 10, 2023
Study Start
October 25, 2023
Primary Completion (Estimated)
June 30, 2028
Study Completion (Estimated)
June 30, 2028
Last Updated
August 7, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ICF
- Time Frame
- Beginning 12 months after publication. No end date.
- Access Criteria
- Researchers who wish to access deidentified data.
Deidentified information will be shared upon request.